Difference between revisions of "Voxelotor (Oxbryta)"
Jump to navigation
Jump to search
m |
m |
||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *11 | + | *2019-11-25: Granted accelerated approval for the treatment of [[Sickle cell anemia|sickle cell disease]] in adults and pediatric patients 12 years of age and older. |
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *2022-02-14: Initial EMA authorization |
==Also known as== | ==Also known as== | ||
Revision as of 01:03, 7 May 2023
Mechanism of action
hemoglobin S polymerization inhibitor
Diseases for which it is used
History of changes in FDA indication
- 2019-11-25: Granted accelerated approval for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older.
History of changes in EMA indication
- 2022-02-14: Initial EMA authorization
Also known as
- Code names: GBT-440, GTx-011
- Brand name: Oxbryta